慢性完全性闭塞病变的病情介绍:重要概念和技术-英文

上传人:aa****6 文档编号:50689262 上传时间:2018-08-10 格式:PPT 页数:49 大小:13.21MB
返回 下载 相关 举报
慢性完全性闭塞病变的病情介绍:重要概念和技术-英文_第1页
第1页 / 共49页
慢性完全性闭塞病变的病情介绍:重要概念和技术-英文_第2页
第2页 / 共49页
慢性完全性闭塞病变的病情介绍:重要概念和技术-英文_第3页
第3页 / 共49页
慢性完全性闭塞病变的病情介绍:重要概念和技术-英文_第4页
第4页 / 共49页
慢性完全性闭塞病变的病情介绍:重要概念和技术-英文_第5页
第5页 / 共49页
点击查看更多>>
资源描述

《慢性完全性闭塞病变的病情介绍:重要概念和技术-英文》由会员分享,可在线阅读,更多相关《慢性完全性闭塞病变的病情介绍:重要概念和技术-英文(49页珍藏版)》请在金锄头文库上搜索。

1、Himeji Cardiovascular CenterHimeji Cardiovascular CenterChronic Total Occlusion(CTO) Case Presentation: Key Concepts and TechniquesTakatoshi Hayashi MD Himeji Cardiovascular Center, Japan2008.4.12 GuangzhouHimeji Cardiovascular CenterHimeji Cardiovascular CenterRole of DES for CTO angioplatyImprove

2、the prognosis?Recent concepts and techniquesCan we treat a patient smartly?CTO angioplastyHimeji Cardiovascular CenterHimeji Cardiovascular CenterRole of DES for CTO angioplatyHimeji Cardiovascular CenterHimeji Cardiovascular CenterCTO angioplasty in DES eraBMSDES(SES)SICCOGISSOCSTOPTOSCANakamuraHoy

3、e0605040103020(%)Re-occlusionRestenosis24%47%34% 32%20%12%8%8%8%3%6%Nakamura2%Ge3%9%9%Himeji Cardiovascular CenterHimeji Cardiovascular CenterSES for CTO lesions:CTO vs Non-CTO Cypher Post Marketing Study (PMS) in JapanHimeji Cardiovascular CenterHimeji Cardiovascular CenterStudy Design (Cypher PMS

4、in Japan) BackgroundPost market evaluation to fulfill a Regulatory Approval Condition Purpose To evaluate the safety and efficacy of the Cypher Sirolimus-eluting coronary stent in routine daily practice in the Japanese population Target Enrollment 2,000 patients (1st year=1,000 patients, 2nd year =1

5、,000patients) No of Sites50 sites (Select sites on basis of balanced population density, hospitals distribution as well as scale of hospitals) Method Prospective Non-randomized Registry Inclusion CriteriaConsecutive patients treated with the Cypher stent(including off abel use) Follow-up In-Hospital

6、,3,8 months and 1,2,3,4,5 years clinical follow-up data :Angiographic follow-up is mandated at 8 months(Analysis:Core lab)Himeji Cardiovascular CenterHimeji Cardiovascular CenterEnrollment Period1st Year: 9/1/043/31/052nd Year: 4/1/059/30/05Intent-to- treatActual Enrollment8M Angiographic F/U12M Cli

7、nical F/U2,054 cases2,051 cases1,752 cases1,857 casesFollow up Rate:85.490.5Delivery Success Rate: 99.8%Study Profile of Cypher PMS in JapanHimeji Cardiovascular CenterHimeji Cardiovascular CenterCTONon-CTOP Value No of lesions109(105pts)2,350(1946pts) RVD, mm 2.280.702.570.6012Mo Consecutive 181 pa

8、tients with 185 lesionsBMS groupSES groupSES available(2004.8-)(Himeji CVC)Himeji Cardiovascular CenterHimeji Cardiovascular CenterCTO angioplasty: BMS vs SES Angiographic results (6Mo-)9.3%BMS (n=74) (Angio F/U 72%)Re-occlusionRestenosis37.8% * :P3.5mm2.25.230mm3.36.90.0010.463Diabetes3.35.70.0120.

9、563In Stent Restenosis3.45.60.0280.596Multi- vessel disease3.55.40.0430.631Prior to PCI3.35.10.0520.625Bifurcation3.45.00.0600.661ACC/AHA Type B2C2.44.30.0710.545Multi- lesion Treatment 4.25.80.3170.707LAD4.33.50.3811.213Prior to MI4.54.10.7021.095TLR Predictors: Japan PMS (1 year)Himeji Cardiovascu

10、lar CenterHimeji Cardiovascular CenterPurposeWe evaluated the clinical results of complex lesions after Cypher Sirolimus-eluting stent implantation as sub-analysis of Cypher Post Marketing Study (PMS) Interim data to 1 year.A Fight with CADA Fight with CADHimeji Cardiovascular CenterHimeji Cardiovas

11、cular CenterStudy Design (Cypher PMS in Japan)BackgroundPost market evaluation to fulfill a Regulatory Approval Condition Purpose To evaluate the safety and efficacy of the Cypher Sirolimus-eluting coronary stent in routine daily practice in the Japanese populationTarget Enrollment 2,000 patients (1

12、st year=1,000 patients, 2nd year =1,000patients)No of Sites50 sites (Select sites on basis of balanced population density, hospitals distribution as well as scale of hospitals)MethodProspective Non-randomized RegistryInclusion CriteriaConsecutive patients treated with the Cypher stent (including off

13、 label use)Follow-up In-Hospital,3,8 months and 1,2,3,4,5 years clinical follow-up data Angiographic follow-up is mandated at 8 months(Analysis:Core lab)Himeji Cardiovascular CenterHimeji Cardiovascular CenterPMS siteHokuto Cardiovascular HospitalSunagawa City HospitalIwate Prefectural Central Hospi

14、tal South Miyagi Medical CenterKatta Hospital Hoshi General HospitalOhra Nishinouchi HospitalNiigata City General HospitalTsukuba Medical Center HospitalSaiseikai Kurihashi HospitalKimitsu Central HospitalShowa University HospitalTeikyo University HospitalMitsui Memorial HospitalInternational Medica

15、l Center of JapanToranomon HospitalItabashi chuo Medical CenterToho University Ohashi Medical CenterSakakibara Heart InstituteMetropolitan Bokutou HospitalShonan Kamakura General HospitalTokai University Hospital Yokohama Sakae Kyosai HospitalKanagawa Cardiovascular and Respiratory CenterComfort Hos

16、pital Toyohashi Heart Center Shizuoka City Shizuoka HospitalAichi Medical UniversityAnjo Kosei Hospital Nagoya Diini Red Cross HospitalShiga Medical Center for AdultsKyoto-Katura HospitalKyoto Second Red Cross HospitalKyoto Universtiy HospitalOtowa HospitalNational Cardiocascular CenterRinku General Medical CenterOsaka Red Cross HospitalOsaka City University HospitalKansai Rosai HospitalHimeji Cardiovascu

展开阅读全文
相关资源
正为您匹配相似的精品文档
相关搜索

最新文档


当前位置:首页 > 办公文档 > PPT模板库 > 教育/培训/课件

电脑版 |金锄头文库版权所有
经营许可证:蜀ICP备13022795号 | 川公网安备 51140202000112号